140944-30-5

Silperisone, also known as RGH-5002; SILA-336, a sodium channel protein type 2 alpha channel blocker potentially for the treatment of spasticity. Silperisone is a tolperisone like organosilicon compound with centrally acting muscle relaxant properties. Silperisone might be a useful antispastic drug. However, findings in chronic animal toxicity studies led to the discontinuation of silperisone's development.

Silperisone hydrochloride is an organosilicone compound similar to tolperisone that has centrally acting muscle relaxant properties. Silperisone (hydrochloride) is a sodium channel protein type 2 alpha channel blocker that blocks sodium and calcium channels in cells, reduces muscle cell excitability and contraction, reduces peripheral tone, and acts as a muscle relaxant and peripheral vascular dilator. Silperisone (hydrochloride) is used to study recurrent painful myoclonus due to spinal cord injury, abnormal hypertonia due to cerebrovascular disease, myotonia symptoms, pyramidal tonia syndrome, multiple sclerosis myospasm, and myelitis[1][2][3].

[1] Farkas S, et al. Simple pharmacological test battery to assess efficacy and side effect profile of centrally acting muscle relaxant drugs[J]. Journal of Pharmacological and Toxicological methods, 2005, 52(2): 264-273. DOI:10.1016/j.vascn.2004.11.005
[2] Kocsis P, et al. Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels[J]. Journal of Pharmacology and Experimental Therapeutics, 2005, 315(3): 1237-1246. DOI:10.1124/jpet.105.089805
[3] Farkas S, et al. Silperisone: a centrally acting muscle relaxant[J]. CNS Drug Reviews, 2006, 12(3‐4): 218-235. DOI:10.1111/j.1527-3458.2006.00218.x